<?xml version='1.0' encoding='utf-8'?>
<document id="19934385"><sentence text="Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir."><entity charOffset="30-42" id="DDI-PubMed.19934385.s1.e0" text="itraconazole" /><entity charOffset="70-79" id="DDI-PubMed.19934385.s1.e1" text="lopinavir" /><entity charOffset="80-89" id="DDI-PubMed.19934385.s1.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.19934385.s1.e0" e2="DDI-PubMed.19934385.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s1.e0" e2="DDI-PubMed.19934385.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s1.e0" e2="DDI-PubMed.19934385.s1.e2" /><pair ddi="false" e1="DDI-PubMed.19934385.s1.e1" e2="DDI-PubMed.19934385.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s1.e1" e2="DDI-PubMed.19934385.s1.e2" /></sentence><sentence text="To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis"><entity charOffset="56-65" id="DDI-PubMed.19934385.s2.e0" text="lopinavir" /><entity charOffset="66-75" id="DDI-PubMed.19934385.s2.e1" text="ritonavir" /><entity charOffset="80-92" id="DDI-PubMed.19934385.s2.e2" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.19934385.s2.e0" e2="DDI-PubMed.19934385.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s2.e0" e2="DDI-PubMed.19934385.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s2.e0" e2="DDI-PubMed.19934385.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19934385.s2.e1" e2="DDI-PubMed.19934385.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s2.e1" e2="DDI-PubMed.19934385.s2.e2" /></sentence><sentence text="" /><sentence text="A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection"><entity charOffset="58-67" id="DDI-PubMed.19934385.s4.e0" text="efavirenz" /></sentence><sentence text=" In the hospital, lopinavir/ritonavir 400 mg/100 mg twice daily replaced efavirenz to avoid efavirenz-itraconazole interactions"><entity charOffset="18-27" id="DDI-PubMed.19934385.s5.e0" text="lopinavir" /><entity charOffset="28-37" id="DDI-PubMed.19934385.s5.e1" text="ritonavir" /><entity charOffset="73-82" id="DDI-PubMed.19934385.s5.e2" text="efavirenz" /><entity charOffset="92-114" id="DDI-PubMed.19934385.s5.e3" text="efavirenz-itraconazole" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e0" e2="DDI-PubMed.19934385.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e0" e2="DDI-PubMed.19934385.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e0" e2="DDI-PubMed.19934385.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e0" e2="DDI-PubMed.19934385.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e1" e2="DDI-PubMed.19934385.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e1" e2="DDI-PubMed.19934385.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e1" e2="DDI-PubMed.19934385.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e2" e2="DDI-PubMed.19934385.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19934385.s5.e2" e2="DDI-PubMed.19934385.s5.e3" /></sentence><sentence text=" After 14 days of liposomal amphotericin B therapy, itraconazole solution was initiated at 150 mg twice daily for 3 days, followed by 200 mg daily"><entity charOffset="28-42" id="DDI-PubMed.19934385.s6.e0" text="amphotericin B" /><entity charOffset="52-64" id="DDI-PubMed.19934385.s6.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.19934385.s6.e0" e2="DDI-PubMed.19934385.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s6.e0" e2="DDI-PubMed.19934385.s6.e1" /></sentence><sentence text=" Prior to itraconazole initiation, lopinavir trough concentration was 7"><entity charOffset="10-22" id="DDI-PubMed.19934385.s7.e0" text="itraconazole" /><entity charOffset="35-44" id="DDI-PubMed.19934385.s7.e1" text="lopinavir" /><pair ddi="false" e1="DDI-PubMed.19934385.s7.e0" e2="DDI-PubMed.19934385.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s7.e0" e2="DDI-PubMed.19934385.s7.e1" /></sentence><sentence text="4 mg/L" /><sentence text=" The lopinavir trough concentration 15 days later, after 14 days of itraconazole, was 6"><entity charOffset="5-14" id="DDI-PubMed.19934385.s9.e0" text="lopinavir" /><entity charOffset="68-80" id="DDI-PubMed.19934385.s9.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.19934385.s9.e0" e2="DDI-PubMed.19934385.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s9.e0" e2="DDI-PubMed.19934385.s9.e1" /></sentence><sentence text="8 mg/L" /><sentence text=" An itraconazole concentration measured 2 hours post-dose on day 15 of oral therapy was 1"><entity charOffset="4-16" id="DDI-PubMed.19934385.s11.e0" text="itraconazole" /></sentence><sentence text="9 microg/mL" /><sentence text=" After 2 weeks of liposomal amphotericin, urine Histoplasma antigen was 27"><entity charOffset="28-40" id="DDI-PubMed.19934385.s13.e0" text="amphotericin" /></sentence><sentence text="23 ng/mL; after 5 months of oral itraconazole therapy, it decreased to 5"><entity charOffset="33-45" id="DDI-PubMed.19934385.s14.e0" text="itraconazole" /></sentence><sentence text="24 ng/mL" /><sentence text=" Plasma HIV RNA decreased 4" /><sentence text="26 log(10) in 5 months to less than 40 copies/mL" /><sentence text=" The patient has demonstrated marked clinical improvement" /><sentence text="" /><sentence text="In this case, dosing recommendations of itraconazole 200 mg daily with lopinavir/ritonavir were appropriate"><entity charOffset="40-52" id="DDI-PubMed.19934385.s20.e0" text="itraconazole" /><entity charOffset="71-80" id="DDI-PubMed.19934385.s20.e1" text="lopinavir" /><entity charOffset="81-90" id="DDI-PubMed.19934385.s20.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.19934385.s20.e0" e2="DDI-PubMed.19934385.s20.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s20.e0" e2="DDI-PubMed.19934385.s20.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s20.e0" e2="DDI-PubMed.19934385.s20.e2" /><pair ddi="false" e1="DDI-PubMed.19934385.s20.e1" e2="DDI-PubMed.19934385.s20.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s20.e1" e2="DDI-PubMed.19934385.s20.e2" /></sentence><sentence text=" Lopinavir trough concentrations were not significantly different following the addition of itraconazole and were above the minimum target of 1 mg/L in treatment-naÃ¯ve patients"><entity charOffset="1-10" id="DDI-PubMed.19934385.s21.e0" text="Lopinavir" /><entity charOffset="92-104" id="DDI-PubMed.19934385.s21.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.19934385.s21.e0" e2="DDI-PubMed.19934385.s21.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s21.e0" e2="DDI-PubMed.19934385.s21.e1" /></sentence><sentence text=" The itraconazole concentration was above the recommended concentration of at least 1 microg/mL"><entity charOffset="5-17" id="DDI-PubMed.19934385.s22.e0" text="itraconazole" /></sentence><sentence text="" /><sentence text="The dose of itraconazole was reduced to 200 mg daily as recommended by current guidelines, and therapeutic drug monitoring of both itraconazole and lopinavir concentrations confirmed that no further dosage adjustments were necessary"><entity charOffset="12-24" id="DDI-PubMed.19934385.s24.e0" text="itraconazole" /><entity charOffset="131-143" id="DDI-PubMed.19934385.s24.e1" text="itraconazole" /><entity charOffset="148-157" id="DDI-PubMed.19934385.s24.e2" text="lopinavir" /><pair ddi="false" e1="DDI-PubMed.19934385.s24.e0" e2="DDI-PubMed.19934385.s24.e0" /><pair ddi="false" e1="DDI-PubMed.19934385.s24.e0" e2="DDI-PubMed.19934385.s24.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s24.e0" e2="DDI-PubMed.19934385.s24.e2" /><pair ddi="false" e1="DDI-PubMed.19934385.s24.e1" e2="DDI-PubMed.19934385.s24.e1" /><pair ddi="false" e1="DDI-PubMed.19934385.s24.e1" e2="DDI-PubMed.19934385.s24.e2" /></sentence><sentence text="" /></document>